Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Avanafil + amlodipine is a combination of two pharmaceutical drugs, each with distinct mechanisms of action and clinical uses. Avanafil is a phosphodiesterase type 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction in adult males. It works by selectively inhibiting PDE5, leading to increased levels of cGMP in the corpus cavernosum during sexual stimulation, resulting in smooth muscle relaxation and enhanced blood flow to the penis[4][6][8]. Amlodipine is a dihydropyridine calcium channel blocker used primarily for treating high blood pressure (hypertension), angina (chest pain), and coronary artery disease. It acts as a peripheral arterial vasodilator by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle cells, thereby reducing peripheral vascular resistance and lowering blood pressure[1][2][7]. The combination may be considered when both indications—erectile dysfunction and hypertension or angina—are present; however, caution is advised due to potential additive effects on lowering blood pressure[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on avanafil + amlodipine.